Back to Search
Start Over
Interleukin-7 and interleukin-15 drive CD4+CD28null T lymphocyte expansion and function in patients with acute coronary syndrome.
- Source :
-
Cardiovascular research [Cardiovasc Res] 2021 Jul 07; Vol. 117 (8), pp. 1935-1948. - Publication Year :
- 2021
-
Abstract
- Aims: Inflammation has important roles in atherosclerosis. CD4+CD28null (CD28null) T cells are a specialized T lymphocyte subset that produce inflammatory cytokines and cytotoxic molecules. CD28null T cells expand preferentially in patients with acute coronary syndrome (ACS) rather than stable angina and are barely detectable in healthy subjects. Importantly, ACS patients with CD28null T-cell expansion have increased risk for recurrent acute coronary events and poor prognosis, compared to ACS patients in whom this cell subset does not expand. The mechanisms regulating CD28null T-cell expansion in ACS remain elusive. We therefore investigated the role of cytokines in CD28null T-cell expansion in ACS.<br />Methods and Results: High-purity sorted CD4+ T cells from ACS patients were treated with a panel of cytokines (TNF-α, IL-1β, IL-6, IL-7, and IL-15), and effects on the number, phenotype, and function of CD28null T cells were analysed and compared to the control counterpart CD28+ T-cell subset. IL-7- and IL-15-induced expansion of CD28null T cells from ACS patients, while inflammatory cytokines TNF-α, IL-1β, and IL-6 did not. The mechanisms underlying CD28null T-cell expansion by IL-7/IL-15 were preferential activation and proliferation of CD28null T cells compared to control CD28+ T cells. Additionally, IL-7/IL-15 markedly augmented CD28null T-cell cytotoxic function and interferon-γ production. Further mechanistic analyses revealed differences in baseline expression of component chains of IL-7/IL-15 receptors (CD127 and CD122) and increased baseline STAT5 phosphorylation in CD28null T cells from ACS patients compared to the control CD28+ T-cell subset. Notably, we demonstrate that CD28null T-cell expansion was significantly inhibited by Tofacitinib, a selective JAK1/JAK3 inhibitor that blocks IL-7/IL-15 signalling.<br />Conclusion: Our novel data show that IL-7 and IL-15 drive the expansion and function of CD28null T cells from ACS patients suggesting that IL-7/IL-15 blockade may prevent expansion of these cells and improve patient outcomes.<br /> (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Subjects :
- Acute Coronary Syndrome metabolism
Aged
CD4-Positive T-Lymphocytes immunology
CD4-Positive T-Lymphocytes metabolism
Cells, Cultured
Cytotoxicity, Immunologic drug effects
Female
Humans
Inflammation metabolism
Interferon-gamma metabolism
Janus Kinase 1 metabolism
Janus Kinase 3 metabolism
Male
Middle Aged
Phenotype
Phosphorylation
STAT5 Transcription Factor metabolism
Signal Transduction
Tumor Necrosis Factor-alpha metabolism
Acute Coronary Syndrome immunology
CD28 Antigens deficiency
CD4-Positive T-Lymphocytes drug effects
Cell Proliferation drug effects
Inflammation immunology
Interleukin-15 pharmacology
Interleukin-7 pharmacology
Lymphocyte Activation drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1755-3245
- Volume :
- 117
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Cardiovascular research
- Publication Type :
- Academic Journal
- Accession number :
- 32647892
- Full Text :
- https://doi.org/10.1093/cvr/cvaa202